Trikaya Global
Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $92.8K Total Trade · DGFT Verified
Trikaya Global is an Indian pharmaceutical exporter with a total trade value of $92.8K across 6 products in 3 therapeutic categories. Based on 58 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ifosfamide ($50.7K), Cladribine ($12.0K), Teicoplanin ($11.2K).
Trikaya Global — Export Portfolio & Destination Treemap
Who is Trikaya Global? — Company Overview & Market Position
Trikaya Global is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2006, the company is headquartered in Mumbai, Maharashtra, India. The registered office is located at Unit No. 1, Sea-view Annexe, No. 18, S. V. Road, Vile Parle West, Mumbai, Maharashtra - 400 002, India. The company operates as a private limited entity, with a paid-up capital of ₹0.10 million, as per the latest available records. Specific details regarding the ownership structure, Corporate Identification Number (CIN), revenue, and employee count are not publicly disclosed. The company's official website is not available, and contact information such as telephone and email addresses are not provided in the available sources.
What Does Trikaya Global Export? — Product Portfolio Analysis
Top Products by Export Value
Trikaya Global Therapeutic Categories — 3 Specializations
Trikaya Global operates across 3 therapeutic categories, with Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), Brand Names & OTC Products (9.0%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 98% of total exports.
Advanced Oncology
4 products · 78.9% · $73.2K
Advanced Antibiotics
1 products · 12.0% · $11.2K
Brand Names & OTC Products
1 products · 9.0% · $8.4K
Product Portfolio — Top 6 by Export Value
Trikaya Global exports 6 pharmaceutical products across 3 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Ifosfamide | Advanced Oncology | $50.7K | 15 | 2.1% | 9 |
| 2 | Cladribine | Advanced Oncology | $12.0K | 7 | 5.1% | 3 |
| 3 | Teicoplanin | Advanced Antibiotics | $11.2K | 11 | 0.2% | 11 |
| 4 | Brufen | Brand Names & OTC Products | $8.4K | 7 | 0.2% | 12 |
| 5 | Daunorubicin | Advanced Oncology | $8.2K | 11 | 1.2% | 10 |
| 6 | Cabozantinib | Advanced Oncology | $2.4K | 7 | 1.9% | 12 |
Trikaya Global exports 6 pharmaceutical products across 3 therapeutic categories with a total export value of $92.8K. The top category is Advanced Oncology (78.9% of portfolio), followed by Advanced Antibiotics (12.0%), indicating a concentrated portfolio with the top 5 products accounting for 97.5% of total export value.
Key Metrics
Top Categories
Top Export Routes
Related Analysis
Trikaya Global — Corporate Profile & Information
Headquarters, ownership, manufacturing facilities, and key leadership
1Corporate Overview
Trikaya Global is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2006, the company is headquartered in Mumbai, Maharashtra, India. The registered office is located at Unit No. 1, Sea-view Annexe, No. 18, S. V. Road, Vile Parle West, Mumbai, Maharashtra - 400 002, India. The company operates as a private limited entity, with a paid-up capital of ₹0.10 million, as per the latest available records. Specific details regarding the ownership structure, Corporate Identification Number (CIN), revenue, and employee count are not publicly disclosed. The company's official website is not available, and contact information such as telephone and email addresses are not provided in the available sources.
2Manufacturing Facilities
Trikaya Global's manufacturing facilities are not explicitly detailed in the available sources. The company is primarily engaged in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. However, specific information regarding the locations, capacities, and specializations of its manufacturing plants is not publicly available.
3Key Leadership
The available sources do not provide specific information about the key leadership of Trikaya Global, including the CEO, CFO, or other key executives. The company's registered office is located at Unit No. 1, Sea-view Annexe, No. 18, S. V. Road, Vile Parle West, Mumbai, Maharashtra - 400 002, India. However, detailed information about the leadership team is not publicly disclosed.
Where Does Trikaya Global Export? — Destination Intelligence
Regulated market presence, emerging market penetration, and geographic strategy
1Regulated Markets
Trikaya Global's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top five exported products include Ifosfamide, Cladribine, Teicoplanin, Brufen, and Daunorubicin, with Ifosfamide leading at $51,000 USD and a 2.1% market share. However, specific information regarding regulatory filings, approvals, and market access status in these regions is not publicly available.
2Emerging Markets
Trikaya Global's penetration into emerging markets such as Africa, Latin America, and Southeast Asia is not explicitly detailed in the available sources. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, specific information regarding the company's presence in emerging markets and WHO prequalification enabling access is not publicly available.
3Geographic Strategy
Trikaya Global's geographic strategy appears to be focused on exporting a diverse range of pharmaceutical formulations across multiple therapeutic categories. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, specific information regarding the company's geographic diversification, concentration risk, and strategic direction is not publicly available.
Trikaya Global — Manufacturing & Regulatory Profile
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
1FDA Status
Specific information regarding Trikaya Global's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top five exported products include Ifosfamide, Cladribine, Teicoplanin, Brufen, and Daunorubicin. However, detailed information regarding FDA approvals and inspection history is not disclosed in the available sources.
2WHO & EU GMP
Specific information regarding Trikaya Global's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding WHO and EU GMP certifications is not disclosed in the available sources.
3CDSCO & Indian Regulatory
Specific information regarding Trikaya Global's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding CDSCO and Indian regulatory approvals is not disclosed in the available sources.
4Recent Regulatory Actions
Specific information regarding recent regulatory actions such as Form 483 observations, warning letters, and import alerts for Trikaya Global is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top five exported products include Ifosfamide, Cladribine, Teicoplanin, Brufen, and Daunorubicin. However, detailed information regarding recent regulatory actions is not disclosed in the available sources.
Trikaya Global — Competitive Positioning Among Indian Pharma Exporters
Market share comparison, key differentiators, and strategic analysis
1Competitive Landscape
Specific information regarding Trikaya Global's top competitors in overlapping categories, market share comparison, and head-to-head analysis is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the competitive landscape is not disclosed in the available sources.
2Key Differentiators
Specific information regarding Trikaya Global's unique strengths, competitive advantages, and product portfolio distinctions is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the company's key differentiators is not disclosed in the available sources.
3Strategic Position
Specific information regarding Trikaya Global's current strategic direction, including focus on generics, specialty products, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, as well as future outlook, is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the company's strategic position is not disclosed in the available sources.
Buyer Due Diligence Brief — Evaluating Trikaya Global as a Supplier
Track record assessment, certifications to verify, and pre-order checks
1Supplier Assessment
Specific information regarding Trikaya Global's overall track record, export volume and consistency, and reliability indicators is not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the company's supplier assessment is not disclosed in the available sources.
2Certifications to Verify
Specific certifications that importers should verify for Trikaya Global, such as FDA approvals, WHO-GMP, EU GMP, and ISO certifications, are not publicly available. The company's export data indicates a total export value of $93,000 USD across 58 shipments, with products spanning six therapeutic categories. The top three therapeutic categories are Advanced Oncology (78.9%), Advanced Antibiotics (12.0%), and Brand Names & OTC Products (9.0%). However, detailed information regarding the company's certifications is not disclosed in the available sources.
3Due Diligence Checklist
Given the limited publicly available information regarding Trikaya Global, importers should consider the following due diligence steps:
- Verify Regulatory Approvals: Confirm that the company's products are approved by relevant regulatory bodies in the target market.
Frequently Asked Questions — Trikaya Global
How many pharmaceutical products does Trikaya Global export from India?
Trikaya Global exports 6 pharmaceutical products across 3 therapeutic categories. The top exports are Ifosfamide ($50.7K), Cladribine ($12.0K), Teicoplanin ($11.2K), Brufen ($8.4K), Daunorubicin ($8.2K). Total export value is $92.8K.
What is Trikaya Global's total pharmaceutical export value?
Trikaya Global's total pharmaceutical export value is $92.8K, based on 58 verified shipments recorded in Indian Customs (DGFT) data.
What therapeutic categories does Trikaya Global cover?
Trikaya Global exports across 3 therapeutic categories. The largest are Advanced Oncology (78.9%, 4 products), Advanced Antibiotics (12.0%, 1 products), Brand Names & OTC Products (9.0%, 1 products).
Get Full Trikaya Global Export Intelligence
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Official References & Regulatory Resources
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Matching: Trikaya Global identified across shipments using name normalization.
- 2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 3.Market Share: Calculated per product as Trikaya Global's capped value divided by total Indian exports for that product.
- 4.Shipment Count: Based on 58 individual customs records matching Trikaya Global.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
6 Products Tracked
3 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Data Source & Methodology
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.